Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy
暂无分享,去创建一个
F. André | M. Lacroix-Triki | B. Asselain | N. Servant | J. Pierga | P. de Cremoux | M. Arnedos | E. Marangoni | C. Nahmias | A. Nehlig | C. Seiler | S. Rodrigues-Ferreira | H. Moindjie | M. Dujaric | S. Chateau-Joubert | Clarisse Monchecourt | P. de Crémoux
[1] A. Vincent-Salomon,et al. Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis , 2018, Breast Cancer Research and Treatment.
[2] V. Villegas,et al. The Role of Chromosomal Instability in Cancer and Therapeutic Responses , 2017, Cancers.
[3] Florence Hubert,et al. Exploring the effect of end-binding proteins and microtubule targeting chemotherapy drugs on microtubule dynamic instability. , 2017, Journal of theoretical biology.
[4] W. Tjalma,et al. Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties. , 2017, European journal of obstetrics, gynecology, and reproductive biology.
[5] L. Pelletier,et al. Mitotic spindle assembly in animal cells: a fine balancing act , 2017, Nature Reviews Molecular Cell Biology.
[6] D. Lambrechts,et al. Centrosome Amplification Is Sufficient to Promote Spontaneous Tumorigenesis in Mammals. , 2017, Developmental cell.
[7] J. Balko,et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.
[8] Sabine Petry. Mechanisms of Mitotic Spindle Assembly. , 2016, Annual review of biochemistry.
[9] M. Burkard,et al. Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer , 2016, BMC Cancer.
[10] L. Pusztai,et al. Predictive and Prognostic Value of the TauProtein in Breast Cancer. , 2015, Anticancer research.
[11] Frédérique Penault-Llorca,et al. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? , 2015, Critical reviews in oncology/hematology.
[12] G. von Minckwitz,et al. Comprehensive Review on the Surrogate Endpoints of Efficacy Proposed or Hypothesized in the Scientific Community Today. , 2015, Journal of the National Cancer Institute. Monographs.
[13] Sarah Watson,et al. Pragmatic issues in biomarker evaluation for targeted therapies in cancer , 2015, Nature Reviews Clinical Oncology.
[14] R. Osan,et al. Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers , 2015, Oncotarget.
[15] X. Tan,et al. Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy , 2015, Tumor Biology.
[16] Georges Noel,et al. Three-Dimensional Cell Culture: A Breakthrough in Vivo , 2015, International journal of molecular sciences.
[17] B. Weaver,et al. How Taxol/paclitaxel kills cancer cells , 2014, Molecular biology of the cell.
[18] Kelly K Hunt,et al. Neoadjuvant therapy in the treatment of breast cancer. , 2014, Surgical oncology clinics of North America.
[19] Mark E. Burkard,et al. Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles , 2014, Science Translational Medicine.
[20] M. Mathieu,et al. Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial. , 2013, Breast.
[21] Lauren M. Zasadil,et al. Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors , 2013, Proceedings of the National Academy of Sciences.
[22] A. Vincent-Salomon,et al. ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics. , 2013, Cancer research.
[23] Yi-long Wu,et al. Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy , 2013, Tumor Biology.
[24] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] L. Harris,et al. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts , 2011, Breast Cancer Research.
[26] C. Nahmias,et al. An ATIPical family of angiotensin II AT2 receptor-interacting proteins , 2010, Trends in Endocrinology & Metabolism.
[27] R. Medema,et al. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells , 2009, Proceedings of the National Academy of Sciences.
[28] A. Vincent-Salomon,et al. 8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis , 2009, PloS one.
[29] David Pellman,et al. A Mechanism Linking Extra Centrosomes to Chromosomal Instability , 2009, Nature.
[30] Alexey Khodjakov,et al. Centrosome Amplification Can Initiate Tumorigenesis in Flies , 2008, Cell.
[31] E. Winer,et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] F. Schmidt. Meta-Analysis , 2008 .
[33] A. Vincent-Salomon,et al. A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.
[34] C. Sotiriou,et al. Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer , 2007, Clinical Cancer Research.
[35] P. Pineau,et al. Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. , 2006, Gene.
[36] J. Ross,et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Z. Szallasi,et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.
[38] Roman Rouzier,et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. Ioannidis,et al. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.
[40] S. Horwitz,et al. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. , 2002, Cancer research.